Ritter Pharmaceuticals Stock Price, News & Analysis (NASDAQ:RTTR)

$0.32 -0.01 (-3.07 %)
(As of 02/16/2018 04:00 PM ET)
Previous Close$0.32
Today's Range$0.30 - $0.33
52-Week Range$0.27 - $3.39
Volume177,694 shs
Average Volume335,725 shs
Market Capitalization$16.03 million
P/E Ratio-0.27
Dividend YieldN/A
Beta0.53

About Ritter Pharmaceuticals (NASDAQ:RTTR)

Ritter Pharmaceuticals logoRitter Pharmaceuticals, Inc. develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company's segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient's health. The Company's compound, RP-G28, is under development for the treatment of lactose intolerance. The Company has completed a Phase IIa clinical trial of its product candidate, RP-G28, an orally administered oligosaccharide. RP-G28 is designed to stimulate the growth of lactose-metabolizing bacteria in the colon. The Company has not generated any revenues.

Receive RTTR News and Ratings via Email

Sign-up to receive the latest news and ratings for RTTR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Bio Therapeutic Drugs
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:RTTR
CUSIPN/A
Phone310-203-1000

Debt

Debt-to-Equity RatioN/A
Current Ratio1.29%
Quick Ratio1.29%

Price-To-Earnings

Trailing P/E Ratio-0.272411444728925
Forward P/E Ratio-0.83
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.35 per share
Price / Book0.90

Profitability

Trailing EPS($1.16)
Net Income$-18,380,000.00
Net MarginsN/A
Return on Equity-480.51%
Return on Assets-235.87%

Miscellaneous

Employees7
Outstanding Shares49,510,000

Ritter Pharmaceuticals (NASDAQ:RTTR) Frequently Asked Questions

What is Ritter Pharmaceuticals' stock symbol?

Ritter Pharmaceuticals trades on the NASDAQ under the ticker symbol "RTTR."

How were Ritter Pharmaceuticals' earnings last quarter?

Ritter Pharmaceuticals Inc (NASDAQ:RTTR) issued its earnings results on Tuesday, October, 31st. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.14) by $0.00. View Ritter Pharmaceuticals' Earnings History.

Where is Ritter Pharmaceuticals' stock going? Where will Ritter Pharmaceuticals' stock price be in 2018?

5 brokerages have issued 12-month price objectives for Ritter Pharmaceuticals' shares. Their predictions range from $1.50 to $5.00. On average, they expect Ritter Pharmaceuticals' stock price to reach $2.50 in the next year. View Analyst Ratings for Ritter Pharmaceuticals.

Who are some of Ritter Pharmaceuticals' key competitors?

Who are Ritter Pharmaceuticals' key executives?

Ritter Pharmaceuticals' management team includes the folowing people:

  • Ira E. Ritter, Executive Chairman of the Board, Chief Strategic Officer (Age 68)
  • Michael D. Step, Chief Executive Officer, Director (Age 57)
  • Jeffrey Benjamin, Principal Financial Officer, Principal Accounting Officer, Vice President - Finance (Age 52)
  • Andrew J. Ritter, President, Founder, Director (Age 34)
  • Noah J. Doyle, Independent Director (Age 49)
  • Matthew W. Foehr, Independent Director (Age 44)
  • Paul V. Maier, Independent Director (Age 69)
  • William M. Merino Ph.D., Independent Director (Age 74)
  • Gerald T. Proehl, Independent Director (Age 58)

When did Ritter Pharmaceuticals IPO?

(RTTR) raised $20 million in an initial public offering (IPO) on Wednesday, June 24th 2015. The company issued 4,000,000 shares at $5.00 per share. Aegis Capital Corp and Chardan Capital Markets served as the underwriters for the IPO and Barrington Research was co-manager.

Who owns Ritter Pharmaceuticals stock?

Ritter Pharmaceuticals' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Sabby Management LLC (0.72%). Company insiders that own Ritter Pharmaceuticals stock include Andrew J Ritter, Matthew W Foehr and Michael D Step. View Institutional Ownership Trends for Ritter Pharmaceuticals.

Who sold Ritter Pharmaceuticals stock? Who is selling Ritter Pharmaceuticals stock?

Ritter Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC. View Insider Buying and Selling for Ritter Pharmaceuticals.

How do I buy Ritter Pharmaceuticals stock?

Shares of Ritter Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ritter Pharmaceuticals' stock price today?

One share of Ritter Pharmaceuticals stock can currently be purchased for approximately $0.32.

How big of a company is Ritter Pharmaceuticals?

Ritter Pharmaceuticals has a market capitalization of $16.03 million. The biotechnology company earns $-18,380,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. Ritter Pharmaceuticals employs 7 workers across the globe.

How can I contact Ritter Pharmaceuticals?

Ritter Pharmaceuticals' mailing address is 1880 CENTURY PARK EAST SUITE 1000, LOS ANGELES CA, 90067. The biotechnology company can be reached via phone at 310-203-1000 or via email at [email protected]


MarketBeat Community Rating for Ritter Pharmaceuticals (RTTR)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  144 (Vote Outperform)
Underperform Votes:  123 (Vote Underperform)
Total Votes:  267
MarketBeat's community ratings are surveys of what our community members think about Ritter Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ritter Pharmaceuticals (NASDAQ:RTTR) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.802.802.832.80
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $2.50$2.50$3.40$5.70
Price Target Upside: 595.99% upside595.99% upside846.55% upside850.00% upside

Ritter Pharmaceuticals (NASDAQ:RTTR) Consensus Price Target History

Price Target History for Ritter Pharmaceuticals (NASDAQ:RTTR)

Ritter Pharmaceuticals (NASDAQ:RTTR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/23/2017Roth CapitalSet Price TargetBuy$2.00N/AView Rating Details
10/23/2017HC WainwrightLower Price TargetBuy -> Buy$7.00 -> $1.50N/AView Rating Details
8/8/2017Chardan CapitalLower Price TargetBuy -> Buy$3.50 -> $1.50MediumView Rating Details
8/4/2017Maxim GroupReiterated RatingHoldLowView Rating Details
3/7/2017AegisReiterated RatingBuyMediumView Rating Details
1/4/2017Rodman & RenshawInitiated CoverageBuy$7.00N/AView Rating Details
(Data available from 2/17/2016 forward)

Earnings

Ritter Pharmaceuticals (NASDAQ:RTTR) Earnings History and Estimates Chart

Earnings by Quarter for Ritter Pharmaceuticals (NASDAQ:RTTR)

Ritter Pharmaceuticals (NASDAQ RTTR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/31/2017Q3 2017($0.14)($0.14)ViewN/AView Earnings Details
8/7/2017Q2 2017($0.15)($0.14)ViewN/AView Earnings Details
5/9/2017Q1 2017($0.38)($0.14)ViewN/AView Earnings Details
2/27/2017Q4 2016($0.35)($0.74)ViewN/AView Earnings Details
11/7/2016Q3 2016($0.50)($0.41)ViewN/AView Earnings Details
8/8/2016Q216($0.34)($0.48)ViewN/AView Earnings Details
5/9/2016($0.32)($0.36)ViewN/AView Earnings Details
3/21/2016Q4($0.34)($0.27)ViewN/AView Earnings Details
11/17/2015Q315($0.40)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Ritter Pharmaceuticals (NASDAQ:RTTR) Earnings Estimates

Current Year EPS Consensus Estimate: $-0.38 EPS
Next Year EPS Consensus Estimate: $-0.3 EPS

Dividends

Dividend History for Ritter Pharmaceuticals (NASDAQ:RTTR)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Ritter Pharmaceuticals (NASDAQ RTTR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 28.10%
Institutional Ownership Percentage: 33.42%
Insider Trades by Quarter for Ritter Pharmaceuticals (NASDAQ:RTTR)
Insider Trades by Quarter for Ritter Pharmaceuticals (NASDAQ:RTTR)

Ritter Pharmaceuticals (NASDAQ RTTR) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/18/2017Matthew W FoehrDirectorBuy18,000$0.62$11,160.0035,000View SEC Filing  
5/11/2017Michael D StepCEOBuy13,000$0.62$8,060.00View SEC Filing  
2/27/2017Michael D StepCEOBuy10,000$2.65$26,500.00View SEC Filing  
2/22/2016Andrew J RitterMajor ShareholderBuy6,250$1.60$10,000.006,250View SEC Filing  
1/8/2016Matthew W FoehrDirectorBuy13,000$1.64$21,320.0017,000View SEC Filing  
1/7/2016Michael D StepCEOBuy27,000$1.48$39,960.0027,000View SEC Filing  
6/24/2015Gerald T ProehlDirectorBuy50,000$5.00$250,000.00View SEC Filing  
6/24/2015Javelin Venture Partners, L.P.Major ShareholderBuy800,000$5.00$4,000,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ritter Pharmaceuticals (NASDAQ RTTR) News Headlines

Source:
DateHeadline
Zacks: Analysts Anticipate Ritter Pharmaceuticals Inc (RTTR) Will Announce Earnings of -$0.05 Per ShareZacks: Analysts Anticipate Ritter Pharmaceuticals Inc (RTTR) Will Announce Earnings of -$0.05 Per Share
www.americanbankingnews.com - February 15 at 3:16 AM
Head to Head Survey: Tocagen (TOCA) & Ritter Pharmaceuticals (RTTR)Head to Head Survey: Tocagen (TOCA) & Ritter Pharmaceuticals (RTTR)
www.americanbankingnews.com - February 4 at 11:08 PM
Ritter Pharmaceuticals (RTTR) Upgraded by ValuEngine to SellRitter Pharmaceuticals (RTTR) Upgraded by ValuEngine to Sell
www.americanbankingnews.com - February 4 at 2:52 PM
Ritter Pharmaceuticals Inc (RTTR) Given Consensus Rating of "Hold" by BrokeragesRitter Pharmaceuticals Inc (RTTR) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - February 2 at 7:22 PM
Ritter Pharmaceuticals Appoints Diane J. Plotkin as Vice President ... - GlobeNewswire (press release)Ritter Pharmaceuticals Appoints Diane J. Plotkin as Vice President ... - GlobeNewswire (press release)
globenewswire.com - January 29 at 3:20 PM
Ritter Pharmaceuticals Appoints Diane J. Plotkin as Vice President of Clinical Development, Ahead of the Launch of its Phase 3 Clinical TrialRitter Pharmaceuticals Appoints Diane J. Plotkin as Vice President of Clinical Development, Ahead of the Launch of its Phase 3 Clinical Trial
finance.yahoo.com - January 29 at 3:20 PM
Critical Contrast: Ritter Pharmaceuticals (RTTR) & The CompetitionCritical Contrast: Ritter Pharmaceuticals (RTTR) & The Competition
www.americanbankingnews.com - January 13 at 7:52 AM
Reviewing Ritter Pharmaceuticals (RTTR) & Its CompetitorsReviewing Ritter Pharmaceuticals (RTTR) & Its Competitors
www.americanbankingnews.com - January 11 at 3:34 PM
Ritter Pharmaceuticals, Inc. (RTTR) Given Average Rating of "Buy" by BrokeragesRitter Pharmaceuticals, Inc. (RTTR) Given Average Rating of "Buy" by Brokerages
www.americanbankingnews.com - January 8 at 10:02 PM
Ritter Pharmaceuticals Inc (NASDAQ:RTTR): Earnings To Drop Next Year, Is It A Long-Term Trend?Ritter Pharmaceuticals Inc (NASDAQ:RTTR): Earnings To Drop Next Year, Is It A Long-Term Trend?
finance.yahoo.com - January 2 at 9:09 PM
Ritter Pharmaceuticals (RTTR) versus The Competition Head-To-Head ReviewRitter Pharmaceuticals (RTTR) versus The Competition Head-To-Head Review
www.americanbankingnews.com - January 1 at 11:32 PM
Analyzing Ritter Pharmaceuticals (RTTR) and Its RivalsAnalyzing Ritter Pharmaceuticals (RTTR) and Its Rivals
www.americanbankingnews.com - December 30 at 1:26 AM
 Analysts Expect Ritter Pharmaceuticals, Inc. (RTTR) to Announce -$0.05 Earnings Per Share Analysts Expect Ritter Pharmaceuticals, Inc. (RTTR) to Announce -$0.05 Earnings Per Share
www.americanbankingnews.com - December 26 at 6:18 PM
Ritter Pharmaceuticals (RTTR) Downgraded by Zacks Investment ResearchRitter Pharmaceuticals (RTTR) Downgraded by Zacks Investment Research
www.americanbankingnews.com - December 26 at 7:36 AM
Try Rising P/E Investing With 5 Top-Ranked Stocks - NasdaqTry Rising P/E Investing With 5 Top-Ranked Stocks - Nasdaq
www.nasdaq.com - December 19 at 3:45 PM
Ritter Pharmaceuticals, Inc. (RTTR) Given Average Recommendation of "Buy" by AnalystsRitter Pharmaceuticals, Inc. (RTTR) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - December 14 at 11:58 PM
Who Are Ritter Pharmaceuticals Inc’s (RTTR) Major Shareholders?Who Are Ritter Pharmaceuticals Inc’s (RTTR) Major Shareholders?
finance.yahoo.com - December 9 at 11:12 AM
Ritter Pharmaceuticals, Inc. (RTTR) Expected to Announce Earnings of -$0.05 Per ShareRitter Pharmaceuticals, Inc. (RTTR) Expected to Announce Earnings of -$0.05 Per Share
www.americanbankingnews.com - December 9 at 1:20 AM
Ritter Pharmaceuticals Changing the Game With Lactose Intolerance Treatment - TheStreet.comRitter Pharmaceuticals Changing the Game With Lactose Intolerance Treatment - TheStreet.com
www.thestreet.com - December 6 at 11:38 AM
Ritter Pharmaceuticals Changing the Game With Lactose Intolerance TreatmentRitter Pharmaceuticals Changing the Game With Lactose Intolerance Treatment
finance.yahoo.com - December 6 at 11:38 AM
Why Ritter Pharmaceuticals Inc (RTTR) Could Be A BuyWhy Ritter Pharmaceuticals Inc (RTTR) Could Be A Buy
finance.yahoo.com - November 30 at 3:45 PM
Pre-Market Technical Scan on Biotech Equities -- Pluristem ... - PR Newswire (press release)Pre-Market Technical Scan on Biotech Equities -- Pluristem ... - PR Newswire (press release)
www.prnewswire.com - November 29 at 3:46 PM
Ritter Pharmaceuticals Presents at the 10th Annual LD Micro Conference on December 5, 2017 - GlobeNewswire (press release)Ritter Pharmaceuticals Presents at the 10th Annual LD Micro Conference on December 5, 2017 - GlobeNewswire (press release)
globenewswire.com - November 29 at 3:46 PM
Ritter Pharmaceuticals Presents at the 10th Annual LD Micro Conference on December 5, 2017Ritter Pharmaceuticals Presents at the 10th Annual LD Micro Conference on December 5, 2017
finance.yahoo.com - November 29 at 11:18 AM
Ritter Pharmaceuticals, Inc. (RTTR) Short Interest UpdateRitter Pharmaceuticals, Inc. (RTTR) Short Interest Update
www.americanbankingnews.com - November 29 at 1:34 AM
Ritter Pharmaceuticals, Inc. (RTTR) Given Consensus Recommendation of "Buy" by AnalystsRitter Pharmaceuticals, Inc. (RTTR) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - November 19 at 5:32 PM
Ritter Pharmaceuticals (RTTR) vs. Nexvet Biopharma plc (NVET) Critical SurveyRitter Pharmaceuticals (RTTR) vs. Nexvet Biopharma plc (NVET) Critical Survey
www.americanbankingnews.com - November 13 at 11:28 AM
Ritter Pharmaceuticals Presents at the 5th Microbiome R&D Business Collaboration Forum / 2nd Annual Probiotic CongressRitter Pharmaceuticals Presents at the 5th Microbiome R&D Business Collaboration Forum / 2nd Annual Probiotic Congress
finance.yahoo.com - November 4 at 12:40 PM
Ritter Pharmaceuticals, Inc. (RTTR) Issues  Earnings ResultsRitter Pharmaceuticals, Inc. (RTTR) Issues Earnings Results
www.americanbankingnews.com - November 1 at 3:50 PM
Ritter Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business UpdateRitter Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
www.nasdaq.com - November 1 at 8:20 AM
Ritter Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business UpdateRitter Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
finance.yahoo.com - October 31 at 8:56 AM
Ritter Pharmaceuticals, Inc. (RTTR) Short Interest Down 58.0% in OctoberRitter Pharmaceuticals, Inc. (RTTR) Short Interest Down 58.0% in October
www.americanbankingnews.com - October 28 at 2:26 AM
Ritter Pharmaceuticals, Inc. (RTTR) Given Average Rating of "Buy" by AnalystsRitter Pharmaceuticals, Inc. (RTTR) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - October 25 at 9:34 PM
Ritter Pharmaceuticals, Inc. (RTTR) Given a $2.00 Price Target at Roth CapitalRitter Pharmaceuticals, Inc. (RTTR) Given a $2.00 Price Target at Roth Capital
www.americanbankingnews.com - October 24 at 6:08 PM
Ritter Pharmaceuticals, Inc. (RTTR) Price Target Cut to $1.50 by Analysts at HC WainwrightRitter Pharmaceuticals, Inc. (RTTR) Price Target Cut to $1.50 by Analysts at HC Wainwright
www.americanbankingnews.com - October 23 at 7:26 AM
Ritter Pharmaceuticals, Inc. (RTTR) Stock Rating Lowered by Zacks Investment ResearchRitter Pharmaceuticals, Inc. (RTTR) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - October 18 at 6:08 AM
Ritter Pharmaceuticals, Inc. Raises $23 Million to Fund Initiation of Its Phase 3 Clinical Program in Lactose IntoleranceRitter Pharmaceuticals, Inc. Raises $23 Million to Fund Initiation of Its Phase 3 Clinical Program in Lactose Intolerance
finance.yahoo.com - October 6 at 7:55 AM
Ritter Pharmaceuticals, Inc. Prices $23,000,000 Public OfferingRitter Pharmaceuticals, Inc. Prices $23,000,000 Public Offering
finance.yahoo.com - October 3 at 11:57 AM
Ritter Pharmaceuticals, Inc. (RTTR) Receives Consensus Rating of "Buy" from AnalystsRitter Pharmaceuticals, Inc. (RTTR) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - September 30 at 8:34 PM
Ritter Pharma (RTTR) Prices $23M Public OfferingRitter Pharma (RTTR) Prices $23M Public Offering
www.streetinsider.com - September 30 at 8:37 AM
Avon, Rite Aid Slide into Fridays 52-Week Low Club - 24/7 Wall St.Avon, Rite Aid Slide into Friday's 52-Week Low Club - 24/7 Wall St.
247wallst.com - September 30 at 12:21 AM
Ritter Pharmaceuticals, Inc. Prices $23000000 Public Offering - GlobeNewswire (press release)Ritter Pharmaceuticals, Inc. Prices $23000000 Public Offering - GlobeNewswire (press release)
globenewswire.com - September 30 at 12:21 AM
Ritter Pharmaceuticals, Inc. (RTTR) Receives Average Recommendation of "Buy" from AnalystsRitter Pharmaceuticals, Inc. (RTTR) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 5 at 9:00 PM
Financial Comparison: Ritter Pharmaceuticals (RTTR) versus Acorda Therapeutics (ACOR)Financial Comparison: Ritter Pharmaceuticals (RTTR) versus Acorda Therapeutics (ACOR)
www.americanbankingnews.com - August 31 at 6:14 AM
Ritter Pharmaceuticals (RTTR) Reports Phase 3 Plans Following End of Phase 2 Meeting with FDA on RP-G28 for LIRitter Pharmaceuticals (RTTR) Reports Phase 3 Plans Following End of Phase 2 Meeting with FDA on RP-G28 for LI
www.streetinsider.com - August 19 at 7:11 AM
Ritter Pharmaceuticals Announces Phase 3 Plans after its End of Phase 2 Meeting with FDA on RP-G28 for Lactose IntoleranceRitter Pharmaceuticals Announces Phase 3 Plans after its End of Phase 2 Meeting with FDA on RP-G28 for Lactose Intolerance
finance.yahoo.com - August 19 at 7:11 AM
 Analysts Anticipate Ritter Pharmaceuticals, Inc. (RTTR) Will Announce Earnings of -$0.17 Per Share Analysts Anticipate Ritter Pharmaceuticals, Inc. (RTTR) Will Announce Earnings of -$0.17 Per Share
www.americanbankingnews.com - August 17 at 6:16 PM
Ritter Pharmaceuticals, Inc. (RTTR) Given Average Recommendation of "Buy" by BrokeragesRitter Pharmaceuticals, Inc. (RTTR) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - August 11 at 11:32 PM
Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) Posts Quarterly  Earnings Results, Meets EstimatesRitter Pharmaceuticals, Inc. (NASDAQ:RTTR) Posts Quarterly Earnings Results, Meets Estimates
www.americanbankingnews.com - August 8 at 1:36 PM
Chardan Capital Trims Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) Target Price to $1.50Chardan Capital Trims Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) Target Price to $1.50
www.americanbankingnews.com - August 8 at 1:20 PM

SEC Filings

Ritter Pharmaceuticals (NASDAQ:RTTR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ritter Pharmaceuticals (NASDAQ:RTTR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ritter Pharmaceuticals (NASDAQ RTTR) Stock Chart for Saturday, February, 17, 2018

Loading chart…

This page was last updated on 2/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.